Mohs Micrographic Surgery in Skin of Color
At the 2023 Skin of Color Update, Dr. David Ciocon, Director of Dermatologic Surgery, Mohs Micrographic Surgery (MMS) and Procedural Dermatology at the Montefiore Medical Center, Albert Einstein College of Medicine, provided a comprehensive exploration of MMS in patients with skin of color, with a focus on defining keratinocyte carcinoma and shedding light on disparities within this patient popula …
At the 2023 Skin of Color Update, Dr. David Ciocon, Director of Dermatologic Surgery, Mohs Micrographic Surgery (MMS) and Procedural Dermatology at the Montefiore Medical Center, Albert Einstein College of Medicine, provided a comprehensive exploration of MMS in patients with skin of color, with a focus on defining keratinocyte carcinoma and shedding light on disparities within this patient popula … Continue reading "Mohs Micrographic Surgery in Skin of Color"
Next Steps in Derm, in partnership with Pigmentary Disorders Exchange Symposium interviewed Dr. Jill S. Waibel, subsection chief of dermatology at Baptist Hospital of Miami, medical director of the Miami Cancer Institute’s Multispecialty Skin Cancer Clinic, and assistant voluntary professor at the University of Miami Miller School of Medicine. Learn about the emerging field of laser-assisted dru … 
Next Steps in Derm, in partnership with Pigmentary Disorders Exchange Symposium interviewed Dr. Diane S. Berson, associate professor of dermatology at Weill Cornell Medical College. Watch as Dr. Berson shares the cosmeceutical ingredients that dermatology clinicians can use synergistically to address photodamage and hyperpigmentation. Learn what ingredients are newly available and how cosmeceutica … 
Ruxolitinib (OPZELURA) is a twice daily topical cream that is FDA approved for non-segmental vitiligo and mild to moderate atopic dermatitis1. JAK inhibitors are a class of drugs effective in treating a wide variety of inflammatory conditions. Initially only FDA approved for non-dermatologic conditions such as rheumatoid arthritis and ulcerative colitis, there is now strong evidence that JAK/STAT … 